Wall Street
Market News

Bringing Affluent Investors and Top Emerging Companies Together!


Stock Alerts Newsletter

Your Full Name: 

Your Email Address: 


  

Subscribe to the Wall Street Market News Stock Alerts Email Newsletter and be among the first to receive breaking news on the markets top emerging companies.

Privacy Policy

Stock Quotes & Charts

Use the most powerful free tools for investors on the internet to help you quickly research your favorite stocks!

StockConsultant
Enter Symbol

Due Diligence

NYSE
AMEX
NASDAQ
OTC Bulletin Board
Pink Sheets
SEC Filings
SEC Database
Hoovers
Barchart.com
Reuters
Financial Glossary
Free Annual Reports
Financial Calculators

Profile Google

Investor Resources

Message Board Directory TradingDay
Quote.com LiveCharts
Yahoo Finance
MSN Money

Smart Money
CNN/Money
Business 2.0
Fortune
Drudge Report
Wikipedia
ZDnet.com
How Stuff Works


Novavax Company Profile!

NVAX
Novavax Inc.
508 Lapp Road
Malvern, PA 19355
Phone: 484-913-1200
Fax: 301-854-3901
Web Site: http://www.novavax.com

Investor FAQ Page
Quote/Chart/Recent News
Arca Web Book
2007 Annual Report
Request Investor Package

Novavax Overview

Novavax, Inc. engages in the research, development, and commercialization of products for women’s health and infectious diseases. Its primary product candidate ESTRASORB, a topical emulsion for estrogen therapy, is used for the treatment of vasomotor symptoms associated with menopause. 

The company’s other products comprise a line of prenatal multivitamin tablets, including Novanatal, NovaStart, and Nestabs for use before, during, and after pregnancy; Gynodiol, an oral estrogen replacement therapy; AVC Cream for the treatment of vaginal infection; and Analpram HC for relief of inflammation and pruritus associated with conditions, such as hemorrhoids and anal fissures. 

Novavax is also developing ANDROSORB, a topical lotion for testosterone replacement therapy in women; ANDRO-Ject, which delivers therapeutic levels of androgen using a subcutaneous testosterone delivery system; and delivery systems, and therapeutic and preventative vaccines for various markets. 

In addition, the company conducts research and development on preventative vaccines and proteins for infectious diseases and cancers; and tolerogens to prevent the initiation and progression of stroke, heart attack, and other inflammatory diseases. 

Novavax has collaborative agreements with the National Institutes of Health for the development of AIDS vaccine and an avian flu vaccine to prevent a pandemic outbreak; National Cancer Institute to develop anticancer vaccines for the treatment of melanoma; NIAID, Walter Reed Army Institute for Research, and GlaxoSmithKline Pharmaceuticals for the development of vaccines to prevent hepatitis caused by Hepatitis E virus; and with Wave Biotech LLC to develop pandemic influenza vaccine production technologies. 

The company sells its products to obstetricians, gynecologists, managed care organizations, wholesalers, and retail pharmacies through direct sales force and distributors in the United States. Novavax was formed in 1987 and is headquartered in Malvern, Pennsylvania.

Is it a Buy, Sell, or Hold?

Members of our exclusive Stock Alerts Investment Newsletter already know the answer to this question and so should you!

Sign Up Now!

Receive the latest analyst commentary, breaking news stories, and articles relating to Novavax by signing up for the Wall Street Market News Stock Alerts Newsletter today. Click here to find out more >